Keywords: Alkermes, Johnson & Johnson, Invega Sustenna, Three month formulation, Schizophrenia, Ph III

Alkermes and J&J initiate Ph III trial of three-month Invega Sustenna

Article | 12 June 2012

Print This

USA-based Alkermes (Nasdaq: ALKS) and partner health care giant Johnson & Johnson (NYSE: JNJ) have started a Phase III clinical ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in